Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Simvastatin-induced rhabdomyolysis.

European journal of neurology·2013

Same author

Cost-effectiveness analysis of general anaesthesia versus local anaesthesia for carotid surgery (GALA Trial).

The British journal of surgery·2010

Same author

General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial.

Lancet (London, England)·2008

Same author

Carotid endarterectomy in the UK: acceptable risks but unacceptable delays.

Clinical medicine (London, England)·2008

Same author

CSF opening pressure: reference interval and the effect of body mass index.

Neurology·2006

Same author

Interventions for treating brain arteriovenous malformations in adults.

The Cochrane database of systematic reviews·2006

Same journal

Global epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Journal of neurology, neurosurgery, and psychiatry·2026

Same journal

Diagnostic accuracy of a two-cut-off approach using the FAQ/MMSE ratio and FAQ for clinical preselection of patients for anti-amyloid therapy.

Journal of neurology, neurosurgery, and psychiatry·2026

Same journal

Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026

Same journal

Visuospatial working memory in Huntington's disease: behavioural and structural brain correlates.

Journal of neurology, neurosurgery, and psychiatry·2026

Same journal

Characteristics and outcomes in electric scooter-related traumatic brain injuries in Helsinki.

Journal of neurology, neurosurgery, and psychiatry·2026

Same journal

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 16, 2026

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Hither neurology: research.

¹Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK.

Journal of Neurology, Neurosurgery, and Psychiatry

|March 1, 1992

Summary

This summary is machine-generated.

Preventing and alleviating neurological disability requires rigorous scientific evaluation of treatments. Proper assessment ensures effective interventions are adopted and ineffective ones abandoned, optimizing healthcare resources.

More Related Videos

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Published on: March 13, 2018

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Experiment Videos

Last Updated: Feb 16, 2026

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Published on: March 13, 2018

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Area of Science:

Neurology
Clinical Research
Health Economics

Background:

Neurological disability presents a significant challenge, necessitating effective prevention and alleviation strategies.
Both laboratory and clinical research are crucial for advancing neurological interventions.
Ensuring the efficacy of treatments is vital for patient outcomes and resource allocation.

Purpose of the Study:

To emphasize the importance of scientific evaluation for all proposed neurological treatments.
To advocate for robust assessment methods to differentiate effective from ineffective interventions.
To highlight the economic and clinical rationale for proper treatment evaluation.

Main Methods:

Discusses the scientific rigor of both laboratory and clinical research in neurology.
Proposes random allocation of patients as the most efficient method for assessing new interventions against existing ones.
Acknowledges historical and ongoing opposition to rigorous treatment evaluation.

Main Results:

Effective interventions must be identified and widely adopted.
Ineffective interventions should be abandoned to conserve resources.
Proper evaluation leads to better targeting of scarce health resources.

Conclusions:

Rigorous evaluation of neurological treatments is essential for clinical practice and public health.
Randomized controlled trials are the gold standard for assessing treatment efficacy.
Economic and clinical arguments strongly support the systematic evaluation of interventions to optimize healthcare delivery.